ACC welcomes one education maven, waves off another

Share this article:
Joseph Green, PhD, will join the American College of Cardiology (ACC) in September as VP for professional development and chief learning officer, marking his return to academic education. He has worked as a consultant since leaving Duke University in 2004, where he was associate dean of CME.

In another senior-level staff move, Marcia Jackson, PhD, senior advisor for education, will leave the college in October, following 15 years there during which she spearheaded a strategic initiative to make ACC’s education more learner-centric. Green will pick up and expand upon her efforts.

Of his new position, Green said, “It’s really trying to do what I’ve been…writing about for years, which is linking CME to physician performance and quality of care.”

ACC has spent years developing learning resources and compiling registry data on physician performance, but new ACC chief executive Jack Lewin, MD, is making the linkage between performance measures and education a strong priority. Doctors must be able to understand their performance to meet maintenance-of-certification requirements from medical specialty boards.
“I’m not going in there to change radically anything they [ACC] have developed,” Green said. “The idea is to see if we can replicate it.”

His focus will be on improving the learning experience for the college’s 33,000 cardiologists and developing new education models, some of which may lend themselves to replication by other societies. Jackson said she plans to move into an independent consulting role.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...